Phuturdex › Diseases › Uterine neoplasm
Drugs in development · updated 30 October 2026
Uterine neoplasm: drugs in development
As of 30 October 2026 there are 24 active clinical trials (recruiting or ongoing, phases I–III) on 61 drugs for uterine neoplasm. 17 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| 9MW2821 | III | 1 | NCT06692166 |
| Puxitatug SamrotecanAZD8205 | III | 1 | NCT07044336 |
| RilvegostomigAZD2936 | III | 1 | NCT06989112 |
| AdavosertibAZD1775 | II | 2 | NCT02465060 |
| Azenosertib | II | 1 | NCT06369155 |
| Coenzyme Q10CoQ10 | I–II | 1 | NCT07668284 |
| FexagratinibAZD4547 | II | 1 | NCT02465060 |
| Ipatasertib | II | 1 | NCT02465060 |
| NEO-201 | I–II | 1 | NCT03476681 |
| Plixorafenib | II | 1 | NCT05503797 |
| Sapanisertib | II | 1 | NCT02465060 |
| Taselisib | II | 1 | NCT02465060 |
| Ulixertinib | II | 1 | NCT02465060 |
| ATV-1601 | I | 1 | NCT07038369 |
| KQB368 | I | 1 | NCT07542704 |
| LunresertibRP-6306 | I | 1 | NCT06107868 |
| ZanzalintinibXL092 | I | 1 | NCT06795009 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PaclitaxelTaxol, Paxlitaxel | III | 6 | NCT06989112 |
| CarboplatinCarboplatine, Paraplatin | III | 4 | NCT06989112 |
| CisplatinCis Platinum, Cisplatine | III | 4 | NCT07831902 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 4 | NCT06989112 |
| DoxorubicinAdriamycin, Doxorubincin | III | 2 | NCT07044336 |
| DocetaxelTaxotere, Beizray® | III | 1 | NCT06989112 |
| Medroxyprogesterone AcetateDepo-Subq Provera 104®, Depo-Provera® | III | 1 | NCT07831902 |
| Megestrol AcetateMegace Es®, Megace® | III | 1 | NCT07831902 |
| Trastuzumab deruxtecanDS-8201a, DS-8201 | III | 1 | NCT06989112 |
| TrastuzumabHerceptin, tratuzumab | II | 2 | NCT02465060 |
| AfatinibGilotrif®, Giotrif® | II | 1 | NCT02465060 |
| BelzutifanWelireg® | II | 1 | NCT06677190 |
| Bevacizumabavastin, MVASI | I–II | 1 | NCT05579366 |
| BinimetinibMEK162, Mektovi® | II | 1 | NCT02465060 |
| CapivasertibAZD5363, Truqap® | II | 1 | NCT02465060 |
Sorted by most advanced phase and number of active trials. Showing 15 of 44 drugs.
All 61 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Endometrial neoplasm 298 drugs
- Uterine cervix neoplasm 224 drugs
- Ovarian neoplasm 411 drugs
- Non-small-cell lung carcinoma 726 drugs
- Colorectal neoplasm 534 drugs
- Stomach neoplasm 340 drugs
- Breast neoplasm 593 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Metastasis 493 drugs
- Triple-negative breast neoplasm 334 drugs
- Melanoma 352 drugs
- Esophageal neoplasm 191 drugs
Broader categories
- Female urogenital disease 11 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Genital Diseases, Female 6 drugs
- Genital Diseases 7 drugs
- Uterine disease 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D014594 “Uterine Neoplasms”.